About the Authors

Nadezhda A. Orlova

Contributed equally to this work with: Nadezhda A. Orlova, Sergey V. Kovnir

Roles Funding acquisition, Investigation, Methodology, Writing – review & editing

Affiliation Laboratory of Mammalian Cell Bioengineering, Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia

Sergey V. Kovnir

Contributed equally to this work with: Nadezhda A. Orlova, Sergey V. Kovnir

Roles Investigation

Affiliation Laboratory of Mammalian Cell Bioengineering, Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia

Yulia A. Khodak

Roles Investigation, Writing – original draft

Affiliation Laboratory of Mammalian Cell Bioengineering, Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia

Mikhail A. Polzikov

Roles Funding acquisition, Investigation, Project administration

Affiliation IVFarma LLC, Moscow, Russia

Victoria A. Nikitina

Roles Investigation, Visualization

Affiliation Laboratory of Radiation Hematology and Cytogenetics, State Research Center-Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russia

Konstantin G. Skryabin

Roles Project administration, Supervision

Affiliation Laboratory of Mammalian Cell Bioengineering, Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia

Ivan I. Vorobiev

Roles Investigation, Methodology, Project administration, Writing – review & editing

ptichman@gmail.com

Affiliations Laboratory of Mammalian Cell Bioengineering, Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia, Laboratory of Biocatalysis, Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia

Competing Interests

KGS declares that he has no competing interests. SVK, NAO and IIV are inventors of the patent RU2488633 which covers the use of the p1.1 plasmid; SVK, NAO, YAK and IIV are inventors of the patent RU2560596 covering the C-P1.3-FSH-G4 cell line. The existence of patents does not alter our adherence to PLOS ONE policies on sharing data and materials. МАР is a stockholder and an employee in the IVFarma LLC (http://ivfarma.ru) that owns rights to the patent RU 2560596. IVFarma LLC also provided support in the form of salary for VAN (short-term service contract). The presence of this commercial affiliation does not alter their adherence to PLOS ONE policies on sharing data and materials.